The financials
Amneal Pharmaceuticals, Inc. by the numbers
Amneal Pharmaceuticals, Inc. (AMRX) reported revenue of $723M in Q1 2026 (quarter ended March 31, 2026), up 3.9% from the same quarter a year earlier. That came with a gross margin of 44% and net income of $62M (8.6% of revenue). For the full year FY2025, revenue was $3.02B (+8.0% year on year) and net income $72M. Its largest product in 2026-Q1 was Subtotal Therapeutic Classes at $133M, 19% of the disclosed total, just ahead of Distribution Service at 13%.
| Income statement | Q1 2026 | Q1 2025 | Change |
|---|---|---|---|
| Revenue | $723M | $695M | +3.9% |
| Gross profit | $320M | $256M | +25% |
| Operating income | $142M | $100M | +41% |
| Net income | $62M | $12M | +411% |
| Diluted EPS | $0.19 | $0.04 | +375% |
| Product | Revenue | Share |
|---|---|---|
| Subtotal Therapeutic Classes | $133M | 19% |
| Distribution Service | $89M | 13% |
| Central Nervous System | $83M | 12% |
| Transdermal | $74M | 11% |
| Government Label | $60M | 8.8% |
| Injectable | $50M | 7.3% |
| Other Dosage Forms | $47M | 6.8% |
| Ephinephrine Auto Injector | $42M | 6.1% |
| Hormonal Allergy | $36M | 5.2% |
| Biosimilar | $22M | 3.3% |
| Other Therapeutic Classes | $14M | 2.0% |
| Oral Liquid | $12M | 1.8% |
| Institutional | $9.8M | 1.4% |
| Product And Service Other | $7.1M | 1.0% |
| International | $5.3M | 0.8% |
Business Segments
Revenue split by product segment, from SEC XBRL filings.
Latest period: Q1 2026Total $684.7M (-6.1%)
International grew +331% year on yearOral Liquid -49% year on year
Segment Latestquarter on quarteryear on year
- Subtotal Therapeutic Classes$133.3M$133.3MQoQ +6.4%year on year +23%+6.4%+23%
- Distribution Service$89.1M$89.1MQoQ -7.3%year on year -15%-7.3%-15%
- Central Nervous System$83.4M$83.4MQoQ +7.4%year on year +23%+7.4%+23%
- Transdermal$74.0M$74.0MQoQ +55%year on year +72%+55%+72%
- Government Label$59.9M$59.9MQoQ -32%year on year +20%-32%+20%
- Injectable$49.9M$49.9MQoQ -8.1%year on year +44%-8.1%+44%
- Other Dosage Forms$46.6M$46.6MQoQ -22%year on year -17%-22%-17%
- Ephinephrine Auto Injector$41.9M$41.9MQoQ -47%year on year -13%-47%-13%
- Hormonal Allergy$35.9M$35.9MQoQ -4.7%year on year +5.1%-4.7%+5.1%
- Biosimilar$22.3M$22.3MQoQ +31%year on year -22%+31%-22%
- Other Therapeutic Classes$13.9M$13.9MQoQ +41%year on year +115%+41%+115%
- Oral Liquid$12.1M$12.1MQoQ -26%year on year -49%-26%-49%
- Institutional$9.8M$9.8MQoQ +68%year on year -11%+68%-11%
- Product And Service Other$7.1M$7.1MQoQ -18%year on year +11%-18%+11%
- International$5.3M$5.3MQoQ -15%year on year +331%-15%+331%
- License Agreement--QoQ -year on year ---
Drug Manufacturers - Specialty & Generic
Ranks #22 of 28 by Smart Score